53,233 Bristol Myers Squibb Company $BMY Shares Acquired by Danske Bank A S

Danske Bank A S lifted its holdings in Bristol Myers Squibb Company (NYSE:BMY) by 3.5% during the third quarter, Holdings Channel reports. The fund owned 1,554,366 shares of the biopharmaceutical company’s stock after buying an additional 53,233 shares during the quarter. Danske Bank A S’s holdings in Bristol Myers Squibb were worth $96,992,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in BMY. Drive Wealth Management LLC lifted its position in Bristol Myers Squibb by 22.0% during the third quarter. Drive Wealth Management LLC now owns 17,184 shares of the biopharmaceutical company’s stock valued at $1,072,000 after purchasing an additional 3,102 shares during the period. McKinney Capital Management LLC grew its position in Bristol Myers Squibb by 8.1% during the 3rd quarter. McKinney Capital Management LLC now owns 24,352 shares of the biopharmaceutical company’s stock worth $1,520,000 after purchasing an additional 1,829 shares during the period. Cornerstone Advisory LLC grew its position in Bristol Myers Squibb by 4.4% during the 3rd quarter. Cornerstone Advisory LLC now owns 6,872 shares of the biopharmaceutical company’s stock worth $429,000 after purchasing an additional 287 shares during the period. Ibex Wealth Advisors purchased a new position in shares of Bristol Myers Squibb during the 3rd quarter valued at about $4,641,000. Finally, Addison Advisors LLC raised its stake in shares of Bristol Myers Squibb by 117.1% during the 3rd quarter. Addison Advisors LLC now owns 1,192 shares of the biopharmaceutical company’s stock valued at $74,000 after buying an additional 643 shares during the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on BMY. Piper Sandler decreased their price objective on Bristol Myers Squibb from $82.00 to $78.00 and set an “overweight” rating for the company in a report on Monday, October 26th. Zacks Research lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 22nd. Roth Capital assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “buy” rating and a $75.00 price target for the company. Jefferies Financial Group reissued a “buy” rating and issued a $76.00 price target on shares of Bristol Myers Squibb in a report on Monday, October 12th. Finally, Daiwa Securities Group boosted their price target on Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $65.46.

Recent Bristol Myers Squibb Headlines

Investors following BMY have been watching these headlines:

• Positive Sentiment: Bristol Myers is working to expand Camzyos’ reach, while Eliquis remains an important contributor to its cardiovascular franchise. Sustained growth in these products could help support revenue. Can BMY Sustain Growth in Its Cardiovascular Franchise?
• Neutral Sentiment: The company plans to unify research and development under one structure, aiming to bring scientific and clinical teams together to speed development and use new technologies. The departure of research chief Robert Plenge adds transition risk, so the impact will depend on execution. BMS sets unified research and development structure for 2027
• Negative Sentiment: Zacks Research cut several earnings forecasts, including FY2026 EPS to $6.44 from $6.86 and FY2028 EPS to $4.77 from $5.21; it also reduced its Q4 2026 and Q2 2027 estimates. These revisions point to a softer earnings outlook, although the firm maintained a Hold rating. Bristol Myers Squibb analyst estimates

Insiders Place Their Bets

In other news, Director Julia Haller sold 3,800 shares of the stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total value of $240,578.00. Following the completion of the sale, the director directly owned 30,279 shares in the company, valued at $1,916,963.49. This represents a 11.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, SVP Phil M. Holzer sold 500 shares of the stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares of the company’s stock, valued at $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Price Performance

Shares of NYSE:BMY traded up $1.07 during trading on Friday, reaching $63.39. The stock had a trading volume of 9,273,842 shares, compared to its average volume of 10,342,026. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.44 and a current ratio of 1.59. Bristol Myers Squibb Company has a 1-year low of $45.26 and a 1-year high of $68.64. The stock has a market cap of $129.57 billion, a PE ratio of 14.06, a PEG ratio of 0.32 and a beta of 0.20. The business has a fifty day moving average price of $61.90 and a 200-day moving average price of $60.31.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, beating the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion during the quarter, compared to the consensus estimate of $12.72 billion. During the same period in the prior year, the company earned $1.63 EPS. The firm’s revenue was up 6.9% compared to the same quarter last year. On average, equities analysts forecast that Bristol Myers Squibb Company will post 6.46 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.0%. Bristol Myers Squibb’s dividend payout ratio is presently 55.88%.

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.